Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
about
Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor.Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.Activity of protease-activated receptors in primary cultured human myenteric neurons.Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonismCell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.Targeting platelet thrombin receptor signaling to prevent thrombosis.PAR-1 inhibitor antiplatelet agents: performance below par?Preventing platelet thrombosis with a PAR1 pepducin.Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.The evolution of antiplatelet therapy in cardiovascular disease.Vorapaxar: a novel protease-activated receptor-1 inhibitor.Novel antiplatelet therapies.Antiplatelet therapy in acute coronary syndromes.Promises of PAR-1 inhibition in acute coronary syndrome.Platelet function and inhibition in ischemic heart disease.Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery diseasePAR-1 antagonists: current state of evidence.Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives.Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Novel anti-platelet agents: focus on thrombin receptor antagonists.Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.Antiplatelet therapy: new pharmacological agents and changing paradigms.Investigational anticoagulants for hematological conditions: a new generation of therapies.New antithrombotics for secondary prevention of acute coronary syndrome.Rivaroxaban in acute coronary syndromes--is it prime time?Recent advances in antithrombotic treatment for acute coronary syndromes.Novel antiplatelet agents in acute coronary syndrome.Myosin di-phosphorylation and peripheral actin bundle formation as initial events during endothelial barrier disruption.Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention.Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.Investigational new drugs for the treatment of acute coronary syndrome.Vein graft failure: from pathophysiology to clinical outcomes.Proteinases, Their Extracellular Targets, and Inflammatory Signaling.Targeting PAR1: Now What?Thrombin receptor antagonism in antiplatelet therapy.
P2860
Q30238719-16B87651-FEC4-4A63-AECE-CAE7F48A2101Q34191373-5C2417A4-DE9C-4609-BC5E-E342B2F870DDQ34282119-9E806552-833A-4BBF-B0B5-A455AEBD6677Q35197451-076A78DB-61BA-4D4B-8F62-C2F60F808420Q36227675-D407449B-922F-4248-8433-3E2914DC1876Q36302146-6B8DA68C-5C8F-4C8C-8447-4D4DE89C60DAQ36532804-1B922507-231C-422D-B1BC-6275A169C9F4Q36813106-004B2AC9-D4D9-4E8F-B685-326D37D6CB52Q37280316-0E12B455-FC72-44C4-9405-A790347239C0Q37387238-EC34D939-3BD8-4629-9C80-B6CE5B586F1DQ37587791-40F1EF11-F3E2-49DC-AEC5-AFB972997420Q37662630-0939FD87-DDAE-4C12-9235-ACCB1B7DA3D4Q37900470-2C340318-5372-405E-B9BE-EB64A5AA2DB8Q37912186-38574A7C-DC37-4BBF-806A-5D78F5779A54Q37958763-4B099B61-6868-4430-B36E-3055BFF8BC4DQ37965609-9DEB63DF-6855-4D6B-B431-5307819B627BQ37967451-3543A588-4813-4BAD-A2E8-A1B8D92178ACQ38007894-AF775D51-E389-424F-AF1B-02A46EB65EAEQ38009321-07BDFA57-0DE7-4DDD-986F-61BA5208B299Q38014344-271FDC4E-67CA-411F-AC68-FAFD136F3156Q38018679-917A7777-A51E-477A-9A7C-F02A37D76CF0Q38032614-BCE773D2-0FED-414F-BD7F-433068A4AB78Q38053481-0D5B19D2-12C7-4237-863C-FAAB624177A6Q38084159-C199099C-E351-49EF-8EEE-D9C4C3EB437BQ38089117-345BB648-883D-4FAD-A8B1-A163AD6B5AD9Q38101275-E9C16DB0-84DF-447F-8C97-9D112B8F3ABDQ38117743-E5108BEF-7967-43C8-A7DC-54077A668BA3Q38123237-93E4A2D0-BFEC-4438-8EB2-A2486B2E27C8Q38180991-5D53C234-B9CD-4376-BC63-C97F181161F2Q38205559-3049324F-09EE-4D29-BE79-031E3E002F4AQ38216600-06FEBD47-C555-4CA7-BD22-BD35D8A76E5AQ38257119-381D2E59-BBBE-4CA0-8D47-B8E254F15CB5Q38364920-566B6ADF-5C16-41E1-8248-D5EC927EAAE1Q38398587-9778723E-C00E-459F-8565-F5ACD323E45EQ38402334-D8E24068-5733-4669-9764-C7D7168199B0Q38594609-B5FD2C66-F388-4C35-9D72-E55D118ECCDCQ38837879-A35A9F75-0852-4CA7-98EE-8AE760ABB730Q38966192-204E5B2A-0B26-4079-A8AE-DA483192B054Q39338913-014A6D9A-C2F5-40DF-B47E-185BDB29B107Q39410704-649AD044-1897-40AF-8567-0728AFEB8025
P2860
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety and tolerability of ato ...... cute Coronary Syndromes Trial.
@en
type
label
Safety and tolerability of ato ...... cute Coronary Syndromes Trial.
@en
prefLabel
Safety and tolerability of ato ...... cute Coronary Syndromes Trial.
@en
P2093
P1433
P1476
Safety and tolerability of ato ...... cute Coronary Syndromes Trial.
@en
P2093
Charles F Contant
Dariusz Dudek
Deepak L Bhatt
Desmond J Fitzgerald
Dominick J Angiolillo
LANCELOT-ACS Investigators
Marcus D Flather
Michelle L O'Donoghue
Philip E Aylward
Rafal Ziecina
P304
P356
10.1161/CIRCULATIONAHA.110.000786
P407
P577
2011-04-18T00:00:00Z